VSIR and congenital rubella syndrome: Importantly, hFlt3L-boosted BRGSF-CBC mice were used to assess the potential toxicity of a novel conditionally active anti-VISTA antibody (SNS-101), and showed no significant CRS features in preclinical settings (manuscript in preparation), as opposed to the anti-VISTA antibody JNJ used in this study.